What is bioAffinity Technologies Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. bioAffinity Technologies's interest expense for the
three
months ended in Mar. 2024 was $ -0.02 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.06 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. bioAffinity Technologies's Operating Income for the
three
months ended in Mar. 2024 was $ -1.95 Mil. bioAffinity Technologies's Interest Expense for the
three
months ended in Mar. 2024 was $ -0.02 Mil.
bioAffinity Technologies did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
bioAffinity Technologies Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
bioAffinity Technologies (NAS:BIAF) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
bioAffinity Technologies's Interest Expense for the
three
months ended in Mar. 2024 was $-0.02 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-1.95 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $1.02 Mil.
bioAffinity Technologies's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| bioAffinity Technologies did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
bioAffinity Technologies (bioAffinity Technologies) Business Description
Traded in Other Exchanges
N/A
Address
22211 W Interstate 10, Suite 1206, San Antonio, TX, USA, 78257
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers.
Executives
| Roby Joyce |
director |
22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257 |
| Xavier Trinidad Reveles |
officer: Chief Operating Officer |
22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257 |
| Michael Philip Dougherty |
officer: Chief Financial Officer |
2934 SCATTERED OAKS ST, SAN ANTONIO TX 78232 |
| James Michael Edwards |
officer: Chief Financial Officer |
30907 KEENELAND DRIVE, FAIR OAKS RANCH TX 78015 |
| Peter S Knight |
director |
6702 STEIN CIRCLE, #642, P.O. BOX 4138, PARK CITY UT 84060 |
| Steven Girgenti |
director, officer: Executive Chairman |
C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013 |
| Robert A. Anderson |
director |
70 DOPPLER, IRVINE CA 92618 |
| Gary D Rubin |
director, 10 percent owner |
2080 NW BOCA RATON BLVD, STE 2, BOCA RATON FL 33431 |
| Stuart Diamond |
director |
498 SEVENTH AVE, NEW YORK NY 10018 |
| Maria Zannes |
director, officer: President, CEO |
19702 BELLA LOMA, #6005, SAN ANTONIO TX 78256 |
| Harvey Sandler Revocable Trust |
10 percent owner |
21170 N. E. 22ND COURT, NORTH MIAMI BEACH FL 33180 |
| Mohsin Y Meghji |
director |
C/O LOUGHLIN MEGHJI + COMPANY, NEW YORK NY 10016 |
| Vivienne I Rebel |
officer: EVP, Chief Sci. & Med. Officer |
8922 APACHE TRAIL, SAN ANTONIO TX 78255 |
| Timothy P Zannes |
officer: Secretary, EVP, Gen. Counsel |
1510 VISTA LARGA CT. NE, ALBUQUERQUE NM 87106 |
| Nathan M Perlmutter |
10 percent owner |
28 PARRISH POND LANE, SOUTHAMPTON NY 11968 |
bioAffinity Technologies (bioAffinity Technologies) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIAF has been successfully added to your 